NBA draft: USC’s Isaiah Collier slides to Jazz with 29th pick in 1st round
https://www.ocregister.com/2024/06/26/nba-draft-uscs-isaiah-collier-slides-to-jazz-with-29th-pick-in-1st-round/
Jun 26, 2024 - After a shaky freshman season with the Trojans, the former top-ranked point guard in the country nearly falls out of the first round on Wednesday night.
0
Baird sees Jazz study failure as positive for rival Praxis
https://seekingalpha.com/news/4118021-baird-sees-jazz-study-failure-as-positive-for-rival-praxis?source=feed_sector_healthcare
Jun 21, 2024 - Baird sees a recent Phase 2 study failure for Jazz's (JAZZ) suvecaltamide having favorable readthrough to Praxis' (PRAX) drug ulixacaltamide in the treatment of essential tremor.
0
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
https://www.zacks.com/stock/news/2291442/jazz-falls-as-suvecaltamide-tremor-study-fails-to-meet-goals?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2291442
Jun 21, 2024 - JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
0
Goldman starts Jazz at buy, cites diversified portfolio
https://seekingalpha.com/news/4113243-goldman-starts-jazz-at-buy-cites-diversified-portfolio?source=feed_sector_healthcare
Jun 05, 2024 - Goldman Sachs initiated coverage of Jazz Pharmaceuticals (JAZZ) with a buy rating, citing its diversified portfolio. Read more here.
0
Jazz presents additional phase 2 data on zanidatamab for biliary tract cancer
https://seekingalpha.com/news/4112139-jazz-presents-additional-phase-2-data-zanidatamab-biliary-tract-cancer?source=feed_sector_healthcare
Jun 01, 2024 - Jazz Pharmaceuticals' zanidatamab shows promising results in treating HER2-positive biliary tract cancer. Read more here.
0
Why Is Jazz (JAZZ) Down 3.5% Since Last Earnings Report?
https://www.zacks.com/stock/news/2282173/why-is-jazz-jazz-down-3-5-since-last-earnings-report?cid=CS-ZC-FT-realtime_blog-2282173
May 31, 2024 - Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
0
Avadel gains for a second day as analysts see it prevailing in case vs Jazz/FDA
https://seekingalpha.com/news/4105409-avadel-gains-for-a-second-day-as-analysts-see-it-prevailing-in-case-vs-jazzfda?source=feed_sector_healthcare
May 13, 2024 - Avadel Pharmaceuticals (AVDL) gains 17% after hearing on dispute over FDA approval for sleep disorder drug amidst patent conflict with Jazz Pharmaceuticals...
0
Axsome (AXSM) Q1 Loss Widens Y/Y, Revenues Beat Estimates
https://www.zacks.com/stock/news/2269767/axsome-axsm-q1-loss-widens-y-y-revenues-beat-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2269767
May 07, 2024 - Axsome's (AXSM) bottom line declines year over year in the first quarter. Strong sales of Auvelity drive revenues.
0
Jazz (JAZZ) Q1 Earnings & Sales Fall Short of Estimates
https://www.zacks.com/stock/news/2267317/jazz-jazz-q1-earnings-sales-fall-short-of-estimates?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2267317
May 02, 2024 - Jazz's (JAZZ) first-quarter earnings and sales miss the mark. The company reaffirms its guidance for full-year 2024.
0
Jazz (JAZZ) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
https://www.zacks.com/stock/news/2266516/jazz-jazz-q1-earnings-taking-a-look-at-key-metrics-versus-estimates?cid=CS-ZC-FT-fundamental_analysis|nfm-2266516
May 01, 2024 - The headline numbers for Jazz (JAZZ) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
0